Pay in 4 interest-free payments of $7.03 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies
(A backlash to the #MeToo movement, maybe?) But if the recent presidential election proved anything, its that young men cant be ignored
At therapeutic doses, tirzepatide has shown greater weight loss outcomes in head-to-head trials
Verdict at a Glance Orforglipron represents a potential paradigm shift as the first oral non-peptide GLP-1 agonist without fasting restrictions, and it demonstrated superiority over oral semaglutide in the head-to-head ACHIEVE-3 trial for both HbA1c and weight loss
While generally recommended for short-term use, some patients may require longer-term treatment under medical supervision
Report persistent, worsening or concerning reactions promptly
